Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
RANDOX LABORATORIES
Bio-Rad Diabetes Division

Expression of Antigen Evaluated for Prostate Cancer

By Labmedica International staff writers
Posted on 14 Feb 2012
The expression of the cancer/testis antigen, A-kinase anchor protein 4 (AKAP-4), has been evaluated in prostate cancer (PC) patients.

The exploitation tumor-associated antigens, not only for screening purposes, but also as targets for tumor immunotherapy underlines their relevance in oncology and is due to features frequently shared by molecular biomarkers and tumor antigens.

Scientists at Texas Technical University (Lubbock, TX, USA) analyzed normal prostate tissues, 15 patients with PC and the LnCAP PC cell line by immunohistochemistry. The immunogenicity of AKAP-4 was tested through indirect enzyme-linked immunosorbent assay (ELISA) on sera from cancer patients and healthy subjects. In vitro AKAP-4-specific cytotoxic lymphocytes were generated from peripheral blood mononuclear cells. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to measure AKAP-4 messenger ribonucleic acid (mRNA) expression.

The AKAP-4 was shown both at the cytoplasmic and surface levels of the LnCAP PC cell line. AKAP-4 was also highly expressed in PC cells from patients. Specific anti-AKAP-4 circulating immunoglobulins were detected in AKAP-4 positive subjects. The use of recombinant AKAP-4-loaded autologous dendritic cells generated AKAP-4-specific and human leukocyte antigen-1 (HLA-I)-restricted cytotoxic T lymphocytes able to kill PC cells in vitro. Further characterization indicated a T-helper cell (Th-1) skewing in the cytokine secretion profile of these cells.

The indirect ELISA was performed using specific reagents from Pierce (Rockford, IL, USA) and the ELISA for T Cell Cytokine Expression used sandwich ELISA kits from U-CyTech (Utrecht, The Netherlands). The authors concluded that the aberrant expression of AKAP-4 in PC will potentially be developed as a biomarker in PC and is a potential target for immunotherapy. The study was published in the January 2012 issue of the journal the Prostate.

Related Links:

Texas Technical University
Pierce
U-CyTech



DiagCor Bioscience
PURITAN MEDICAL
77 ELEKTRONIKA
comments powered by Disqus
Sekisui Diagnostics

Channels

Clinical Chemistry

view channel
Image: The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics).

Low Density Lipoprotein Apolipoprotein-B Assay Validated

The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol... Read more

Genetic Tests

view channel
Histopathology of colonic adenocarcinoma; the glands are enlarged and filled with necrotic debris (Photo courtesy of the University of Utah).

Promising Blood Biomarkers Isolated for Colorectal Cancer

The search for blood-borne biomarkers that could be used to screen for colorectal cancer (CRC) has uncovered two promising candidates that may one day lead to the development of a simple blood test.... Read more

Microbiology

view channel

Novel Sequence Analysis Services Improve Pathogen Identification

A set of new-generation sequencing (NGS) services provides unique tools for more effective identification of known and unknown microorganisms, including bacterial, viral, fungal, and protozoan parasite pathogens. Aperiomics (Ashburn, VA, USA) has now introduced its breakthrough Absolute-NGS Pathogen Detection Platform... Read more

Industry News

view channel

Market for qPCR Exceeds USD 3 Billion

The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.